東曜藥業-B(01875.HK)上半年淨利3155.9萬元 實現扭虧為盈
格隆匯8月13日丨東曜藥業-B(01875.HK)公吿,2024上半年集團營業收入為人民幣5.2億元,同比增長59%。其中產品銷售收入為人民幣4億元,同比增長44%,主要來自核心產品貝伐珠單抗注射液樸欣汀®銷量持續攀升。CDMO/CMO業務收入達人民幣1.14億元,同比增長144%。造血能力穩健,上半年經營活動現金淨額為人民幣27,801千元,持續保持正向。戰略轉型CDMO成果顯著,自研產品銷售也穩步提升。實現扭虧為盈,上半年淨利潤達人民幣3155.9萬元。
生物藥CDMO市場地位持續提升,上半年新增項目20個,累計至115個,新增項目中,17個為ADC;新增2個pre-BLA(上市前臨牀申報)項目,累計在手8個,鎖定未來商業化生產;已簽約未完成訂單達人民幣1.84億元,同比增長104%;國內外客訪次數不斷上升,品牌影響力持續擴大。
公司滿足中國、美國、歐洲GMP標準的質量管理體系,獲得了國內外業界廣泛的認可。截至2024年6月30日,累計接受60多次GMP審計,包含零缺陷通過歐盟QP審計,現場直接通過哥倫比亞官方GMP審計,以及通過印尼、埃及等國家GMP審計。此外,其中公司還多次配合客户完成海外合作方跨國藥企的檢查以及機構檢查,成功配合客户完成授權並獲得高度認可。
持續加強CDMO團隊能力。為滿足CDMO業務快速發展,CDMO人員同比增長29%,至492人,佔集團總人數86%。ADCCDMO團隊同比增幅27%,強化業務重心。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.